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Abstract
Background: Age-related macular degeneration (AMD) is a disease with multiple risk factors,
many of which appear to involve oxidative stress. Macular pigment, with its antioxidant and light-
screening properties, is thought to be protective against AMD. A result has been the appearance
of dietary supplements containing the macular carotenoids, lutein and zeaxanthin. More recently, a
supplement has been marketed containing, in addition, the third major carotenoid of the macular
pigment, meso-zeaxanthin. The purpose of the study was to determine the effectiveness of such a
supplement in raising macular pigment density in human subjects.
Methods: A 120 day supplementation study was conducted in which 10 subjects were given gel-
caps that provided 20 mg/day of predominantly meso-zeaxanthin, with smaller amounts of lutein
and zeaxanthin. A second group of 9 subjects were given gel caps containing a placebo for the same
120 day period. Prior to and during the supplementation period, blood serum samples were
analyzed by high performance liquid chromatography for carotenoid content. Similarly, macular
pigment optical density was measured by heterochromatic flicker photometry. Differences in
response between the supplementation and placebo groups were tested for significance using a
student's t-test.
Results: During supplementation with the carotenoids, blood samples revealed the presence of all
three carotenoids. Macular pigment optical density, measured at 460 nm, rose at an average rate
of 0.59 ± 0.79 milli-absorbance unit/day in the 10 supplemented subjects. This was significantly
different from the placebo group (9 subjects) for whom the average rate was -0.17 ± 0.42 milli-
absorbance units/day.
Conclusion: We have shown for the first time that meso-zeaxanthin is absorbed into the serum
following ingestion. The data indicate that a supplement containing predominantly meso-zeaxanthin
is generally effective at raising macular pigment density, and may turn out to be a useful addition to
the defenses against AMD.
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Background
Macular pigment (MP), first identified in the mid-1980s
as a combination of lutein and zeaxanthin [1-3], was sub-
sequently shown to be characterized by the presence of
specific stereoisomers of these two carotenoids [4]. While
lutein (L) is present as a single stereoisomer,
[(3R,3'R,6'R)-β,  ε-carotene-3,3'-diol], zeaxanthin occurs
primarily as a mixture of [(3R,3'R)-β, β-carotene-3,3'-diol]
and [(3R,3'S)-β,  β-carotene-3,3'-diol], with a much
smaller amount of [(3S,3'S)-β, β-carotene-3,3'-diol]. The
first two predominant zeaxanthin isomers are referred to
as zeaxanthin (Z) and meso-zeaxanthin (MZ), respectively.
Of these carotenoids, only L and Z are normally con-
sumed in a roughly seven-to-one ratio [5] whereas MZ is
an unusual and consequently rare isomer in the diet. MZ
is present in significant quantities in commercially pro-
duced chickens and eggs in Mexico where it is commonly
added to the feed to achieve desirable coloration in these
products. Approximately 3000 kg of MZ are sold each year
for this purpose [6]. In the US population, L and Z are
abundant in the serum, but MZ cannot normally be
detected in the serum. This observation led to a hypothe-
sis that MZ is formed in the retina as a conversion product
of L [4,7]. In vitro, the conversion of L into MZ is readily
achieved in a base-catalyzed reaction [4], and this is the
basis of an industrial process for its synthesis and use in
poultry feed. The conversion hypothesis is supported by
the distribution of the individual carotenoids in the ret-
ina. In the central 10°, there is more MZ and less L relative
to Z, whereas in the periphery (>35° eccentricity) the sit-
uation is reversed [8]. This suggests that the postulated
conversion process operates with greater efficiency in the
foveal center compared with the peripheral retina. Mon-
keys raised on a carotenoid-free diet, and then supple-
mented with L only, subsequently exhibited both L and
MZ in the MP. Those supplemented with Z only exhibited
no MZ in their MP, only Z. These data are strong evidence
in support of the L-to-MZ conversion hypothesis [9].
The absolute configuration of the hydroxyl groups located
on the 3 and 3' carbon atoms of the carotenoid end-
groups is identical in the L and MZ molecules. Thus the
conversion of L into MZ need only involve a shift of one
carbon-carbon double bond in the ε-ring of L, thereby
increasing the conjugation (see Fig. 1). An alternative
mechanism for the formation of MZ posits that the
metabolite, dehydrolutein, gives rise to MZ through an
enzymatic reduction pathway [10]. Indeed the keto-caro-
tenoid canthaxanthin does undergo reduction in the
human and primate retina lending credence to this possi-
bility [11]. However, in plasma, dehydrolutein is formed
from both L [12] and Z [13]. If these processes also occur
in the eye, and MZ is formed from this metabolite, it
should have been found in Z- as well as L-supplemented
monkeys. Whatever pathway is involved, it would proba-
bly involve enzymatic control in order to be consistent
with the observation that the proportion of MZ within the
retina is dependent upon the location.
At this stage we can speculate on the possible advantages
that such a conversion might afford to the eye. It has been
proposed that MP protects the macula by two processes
[14]. Its presence in the photoreceptor axons [15],
together with the range of spectral absorbance (~400 –
500 nm) provides MP with the ability to shield posterior
tissues, such as the photoreceptor outer segments and the
RPE, from actinic blue light. Additionally, its presence in
the outer segments and RPE [16,17] may mitigate the
photooxidative damage caused by blue light [18] via its
antioxidant and free-radical scavenging properties. In
vitro experiments indicate that Z is a more potent antioxi-
dant than L [18]. In one study, quenching of singlet oxy-
gen by Z was approximately twice as effective as
quenching by L [19]. The reason is presumably due, at
least in part, to the extended conjugation of Z compared
with L. MZ shares this electronic feature with Z and there-
fore should possess the same antioxidant potential as Z. It
has also been reported that in association with a zeaxan-
thin binding protein, the pi isoform of glutathione S-
transferase, MZ provides slightly better protection against
lipid membrane oxidation than Z [20]. Without the bind-
ing protein, the situation is reversed. Thus it may be
advantageous to the macula to increase the ratio of total
zeaxanthin (Z+MZ) to L. In the serum the ratio of Z to L is
about 1:4. A secondary advantage may be the modest but
significant shift to longer wavelengths of the Z chromo-
phore relative to that of L resulting in an increase in the
wavelength range of blue light screening compared with
that which would be provided if the MP was predomi-
nantly composed of L. A third advantage may arise from
the actual placement of the carotenoid molecules. Obser-
vations indicate that L and Z may be present within cellu-
lar membranes [21,22]. Z appears to span the membrane
in a perpendicular orientation whereas L tends to lie close
to the membrane surface [23]. These configurations place
Z's protective oxidation sites closer to the readily oxidiza-
ble polyunsaturated fatty acid chains in the interior of the
membrane.
The purpose of the study was to investigate the potential
of ingested MZ in combination with L and Z to increase
the optical density of MP. The study was motivated by the
recent emergence of dietary supplements containing sig-
nificant amounts of MZ in addition to L and Z.
Methods
Subjects
Eight male and 2 female subjects were recruited from the
University community for the supplementation study.
Their ages ranged from 21 to 58 years (mean 30.5 ± 10.9Nutrition & Metabolism 2007, 4:12 http://www.nutritionandmetabolism.com/content/4/1/12
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years). Two more subjects were recruited for a more
detailed analysis of blood serum carotenoids. Their ages
were 51 and 61. Subsequently, a comparison group of
subjects was recruited to receive a placebo (placebos only
became available after the study had been initiated). The
group consisted of 5 males and 4 females with an age
range of 19 to 31 years (mean 22.1 ± 3.6 years). While our
study did not conform to the standard, double blind, pla-
cebo-controlled trial in which subjects are randomly
assigned to the treatment and placebo groups, it did offer
the opportunity of distinguishing MP changes due to sup-
plementation from those that might occur on a more ran-
dom basis. It should also be noted that the study took
place in South Florida where the diet tends not to be sea-
sonal owing to the constant availability of commonly
consumed fruits and vegetables. Therefore we believe that
not running the supplementation and placebo groups
concurrently would not introduce a bias into the results.
Furthermore, while the difference in the mean ages of the
groups was just significant (p < 0.05), we are not aware of
any age-related differences in the ability of individuals to
modify their MP by supplementation.
Exclusion criteria for potential subjects were 1) being a
smoker or having smoked in the previous 12 months, 2)
any visual pathology, 3) inability during practice sessions
to provide acceptable MP optical density (MPOD) meas-
urements, and 4) the use of oral supplements containing
significant (>0.25 mg/day) amounts of L and/or Z. Apart
from the latter restriction, subjects were free to follow
their normal diet. Subjects signed an informed consent
form in accordance with the requirements of the Institu-
tional Review Board, and the study conformed to the ten-
ets of the Declaration of Helsinki. Each subject was given
training in heterochromatic flicker photometry, the
method used to determine MPOD. Official enrollment in
the study followed a practice period during which the sub-
jects were required to achieve acceptable MPOD measure-
ments (standard error in the mean based on a set of 5
central and 5 peripheral settings ≤ 0.020 absorbance units.
See below.).
Supplementation
Subjects in the supplementation group were given sup-
plies of gel caps containing unesterified carotenoids: 14.9
mg of MZ, 5.5 mg of L, and 1.4 mg of Z as a suspension in
soybean oil, and were informed of the contents. The com-
position of the gel caps was determined by HPLC (see
below). The carotenoid mixture was produced by Indus-
trial Orgánica SA (Monterrey, Mexico) in a base-catalyzed
reaction of carotenoids (~93% L, 7% Z) extracted from
marigolds (Targetes sp.). Safety of MZ has been verified in
a recent toxicity trial. Based on the trial, the no-observed-
adverse-effect-level (NOAEL) of MZ in rats was >200 mg/
Structures of the major constituents of the macular pigment Figure 1
Structures of the major constituents of the macular pigment.Nutrition & Metabolism 2007, 4:12 http://www.nutritionandmetabolism.com/content/4/1/12
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kg/day [24]. The product has also been tested for muta-
genicity, using the Ames test, with negative results [25].
Subjects in the placebo group were given gel caps contain-
ing only a small quantity of vegetable oil. Unlike those in
the supplementation group, the placebo group was
blinded, being informed that the gel caps contained either
carotenoids or a placebo. Subjects in both groups were
instructed to take the gel caps on a daily basis, with a
meal, for a period of 120 days.
MPOD measurements
MPOD was determined for each subject by heterochro-
matic flicker photometry (HFP) [26]. The subjects viewed
a 1.5° stimulus that alternated between 460 and 540 nm,
and adjusted the intensity of the former until flicker was
minimized. Five repeat adjustments were made while
viewing the stimulus centrally (frequency 30 Hz), and 5
repeat reference adjustments were made while viewing the
stimulus peripherally at 8° eccentricity (frequency 22 Hz).
After each setting, the wedge filter controlling the 460 nm
intensity was automatically given a random offset. The log
ratio of the averages of the two sets of intensity measure-
ments is equal to the difference in MPOD at 460 nm
between the fovea and the peripheral reference site.
Assuming MPOD is negligible at the peripheral site, the
procedure essentially provides the average MPOD within
the central 1.5° [27]. However, this may not be the case
for subjects receiving high doses of carotenoids. Rod-
riguez-Carmona et al. found that after supplementation
with 20 mg per day of L and/or Z, the slope of the MPOD
distribution remained finite even as far out as 8° eccen-
tricity [28] implying that MPOD could not be assumed to
be zero at this location. Thus the central MPOD may be
slightly underestimated by HFP at the end of a supple-
mentation study, even if the procedure employs a refer-
ence site as far out as 8°. Also, in the parafovea (5.5°
eccentricity), MPOD may, according to one study [29],
increase with age and this, for the same reason, could
cause an apparent decrease in central MPOD with age
when using a 5.5° or, conceivably, an 8°, reference site.
MPOD measurements were made at least 4 times prior to
supplementation, then twice weekly during the 120 day
supplementation period and for the 4 week period follow-
ing supplementation. (Allowances were made for holi-
days, etc., resulting in occasional gaps in the data.) It
should be noted that these measurements represent a self-
administered test with no intervention by the operator.
The subjects record each wedge setting by pressing a push-
button and a microprocessor automatically calculates
their MPOD and associated standard error in the mean.
This effectively eliminates any operator or subject bias
that might otherwise differentially influence the results of
either the MZ or placebo groups.
Serum analysis of carotenoids
Serum samples were obtained from each subject in order
to monitor changes in L and Z concentration. Analysis was
conducted by an assistant who was blinded with regard to
the origin of the serum samples (MZ or placebo). Two
samples were obtained prior to supplementation to estab-
lish a baseline. During supplementation, serum samples
were obtained every 2 weeks. Carotenoids were extracted
from serum by methods that have been described previ-
ously [30], and included the addition, prior to extraction,
of a known amount of an internal standard (monopentyl
lutein ether) to each milliliter of serum. HPLC of the
extracts was conducted on a reversed-phase system using
a 250 × 4.6 mm Ultracarb ODS 3 μm column (Phenom-
enex, Torrance CA). The mobile phase was acetonitrile/
methanol (85:15) at 1 mL/min with 0.1% triethylamine
added to inhibit degradation of carotenoids during elu-
tion.
This system is capable of producing baseline separation of
L and the combined zeaxanthin stereoisomers, but does
not separate Z from MZ. In order to determine whether
MZ was absorbed into the serum along with L and Z,
serum samples were obtained from 2 additional subjects,
A and B, prior to supplementation and after 6 weeks of
supplementation. Carotenoids extracted from these sam-
ples were analyzed by HPLC on a 250 × 4.6 mm Chiralpak
AD column consisting of a silica support derivatized with
a chiral polysacharide (Daicel Chemical Industries,
Osaka, Japan) and a using a mobile phase consisting of
hexane and isopropyl alcohol. Elution was carried out at
a flow rate of 0.8 mL/min starting at 90% hexane and 10%
isopropyl alcohol and increasing to 100% hexane over a
55 min gradient. Stereoisomers were identified by com-
parison with the elution order of known standards.
The same systems were used for the analysis of caroten-
oids in the supplement.
Results
The presence in the serum of MZ, in addition to L and Z,
resulting from supplementation was confirmed in the two
subjects, A and B, who participated in this part of the
study. Prior to supplementation, the serum concentra-
tions of L, Z, and MZ were 22.9, 4.4, and 0.0 nmol/dL, and
14.8, 2.1, and 0.0 nmol/dL, for subjects A and B respec-
tively. After 6 weeks of supplementation, these values
were 23.9, 8.7, and 4.4 nmol/dL for subject A, and 45.4,
15.4, and 14.5 nmol/dL for subject B.
For the other 10 subjects in the supplementation study
(subject #s 1–10), we determined the increases in L and
combined Z + MZ in the serum by averaging each subject's
pre-supplementation values as well as the values obtained
from week 6 to the end of the supplementation period.Nutrition & Metabolism 2007, 4:12 http://www.nutritionandmetabolism.com/content/4/1/12
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The latter average was not affected by the increase in caro-
tenoid concentration in the serum that normally occurs
during the early phase of supplementation [31]. The
results are shown in Table 1. Prior to supplementation,
the average concentrations for the 10 subjects were 30.5 ±
12.5 (range 16.4 to 54.2) nmol/dL for L, and 9.7 ± 4.8
(range 3.6 to 19.0) nmol/dL for Z + MZ. During supple-
mentation (i.e. from week 6 to the end of supplementa-
tion), these values rose to 38.0 ± 12.0 (range 24.2 to 62.3)
nmol/dL for L, and 26.4 ± 6.5 (range 13.6 to 35.0) nmol/
dL for Z + MZ.
For the placebo group (subject #s 11–19), the average
serum L of the subjects changed from 19.5 ± 6.4 (range 4.6
to 27.9) prior to taking the placebo to 30.7 ± 22.8 (range
6.4 to 79.1) nmol/dL from week 6 to the end of "supple-
mentation." For Z, the value changed from 7.6 ± 3.4
(range 2.1 to 10.0) to 15.8 ± 15.3 (range 2.9 to 50.3)
nmol/dL. Neither of these average changes, which may
have been due to dietary changes, was significant accord-
ing to a 2-sided t-test (p = 0.14 for L, p = 0.13 for Z), nor
was any individual change significant.
Table 1: Serum responses for 10 subjects in supplementation group. Baseline and plateau values refer to averages obtained prior to 
supplementation and from week 6 to the end of supplementation, respectively.
Subject Number Baseline L concentration ± SD 
(nmol/dL)
Plateau L concentration ± SD 
(nmol/dL)
Baseline Z+MZ concentration ± 
SD (nmol/dL)
Plateau Z+MZ concentration ± 
SD (nmol/dL)
1 36.9 ± 17.8 42.4 ± 6.7 5.6 ± 0.4 25.1 ± 5.2
2 16.4 ± 1.9 34.1 ± 12.3 7.4 ± 1.6 34.9 ± 15.4
3 22.6 ± 3.5 26.3 ± 2.7 8.7 ± 1.1 22.9 ± 3.7
4 35.8 ± 1.8 36.4 ± 6.9 14.1 ± 5.6 29.6 ± 8.8
5 18.2 ± 1.4 25.5 ± 5.8 6.1 ± 0.4 22.1 ± 5.7
6 42.7 ± 0.9 62.3 ± 18.1 19.0 ± 3.0 35.0 ± 9.3
7 16.7 ± 3.3 24.2 ± 4.9 7.3 ± 0.9 13.6 ± 3.5
8 54.2 ± 5.2 45.2 ± 10.6 11.0 ± 4.0 30.4 ± 0.8
9 34.0 ± 6.8 49.1 ± 4.2 14.0 ± 3.8 27.0 ± 1.2
10 27.1 ± 3.8 34.6 ± 1.2 3.6 ± 2.6 23.4 ± 0.6
Mean ± SD 30.5 ± 12.5 38.0 ± 12.0 9.7 ± 4.8 26.4 ± 6.5
Table 2: Macular pigment optical density (MPOD) response to supplementation. MPOD data for the supplementation group obtained 
prior to supplementation together with the rates of change in MPOD during supplementation. The p-values indicate whether these 
rates are significantly different from zero. (AU = absorbance unit)
Subject/eye MPOD pre AU SD pre AU Rate of change in MPOD ± SE, mAU/day p Significance of rate of change
1/L 0.421 0.016 2.22 ± 0.11 < 0.0001 Signif. increase
1/R 0.446 0.025 2.01 ± 0.06 < 0.0001 Signif. increase
2/L 0.779 0.015 -0.18 ± 0.30 0.57 No signif. change
2/R 0.679 0.016 0.17 ± 0.38 0.66 No signif. change
3/L 0.286 0.018 0.27 ± 0.10 0.012 Signif. increase
3/R 0.306 0.011 -0.04 ± 0.09 0.69 No signif. change
4/L 0.468 0.019 1.23 ± 0.21 < 0.0001 Signif. increase
4/R 0.355 0.022 1.58 ± 0.28 < 0.0001 Signif. increase
5/L 0.254 0.018 0.51 ± 0.14 0.0009 Signif. increase
5/R 0.265 0.027 -0.46 ± 0.18 0.016 Signif. decrease
6/L 0.351 0.019 -0.22 ± 0.16 0.18 No signif. change
6/R 0.362 0.014 0.02 ± 0.21 0.94 No signif. change
7/L 0.335 0.017 0.92 ± 0.34 0.015 Signif. increase
7/R 0.304 0.02 -0.57 ± 0.35 0.12 No signif. change
8/L 0.718 0.013 0.65 ± 0.25 0.016 Signif. increase
8/R 0.722 0.014 0.44 ± 0.32 0.17 No signif. change
9/L 0.344 0.012 1.07 ± 0.29 0.0009 Signif. increase
9/R 0.421 0.011 1.33 ± 0.35 0.0008 Signif. increase
10/L 0.96 0.008 0.43 ± 0.05 < 0.0001 Signif. increase
10/R 0.854 0.008 0.41 ± 0.04 < 0.0001 Signif. increaseNutrition & Metabolism 2007, 4:12 http://www.nutritionandmetabolism.com/content/4/1/12
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MPOD response in each subject was quantified by calcu-
lating the average rate of change in MPOD, measured in
milliabsorbance units per day (mAU/day), and the associ-
ated standard error (SE) for each eye of each subject dur-
ing the study period. Data for the left eye of subject # 1
(supplementation group), who had a particularly robust
response and little scatter in the MPOD measurements,
and for the right eye of subject # 6 (supplementation
group), who had no significant change in MPOD com-
bined with a lot of scatter, are shown in Fig. 2. The short-
term, session-to-session variability is typical of data
obtained by HFP, and is probably a measurement artifact.
The rate of change in MPOD for each eye of each subject
was calculated using all MPOD measurements for that eye
from day zero (start of supplementation) onwards. Based
on the observation that some subjects (e.g. subjects 2, 4,
9) had significantly different initial MPODs in their left
and right eyes, we have treated the responses in each eye
of a subject as independent observations. The complete
results for the supplementation group are presented in
Table 2. The table includes p-values, based on a 2-sided t-
test, that indicate whether the measured rates of change in
MPOD were significantly different from zero. Significant
rates of increase in MPOD were observed in 12 eyes, no
significant changes occurred in 7 eyes, and, surprisingly, a
significant decrease occurred in one eye.
MPOD results for the placebo group are shown in the
same format in Table 3. For one subject, there was a signif-
icant decrease in MPOD in both eyes, and for another sub-
ject, there was a significant decrease in one eye only. No
significant changes in MPOD were observed in any other
subject's eye in the placebo group.
Discussion
Data from subjects A and B indicate for the first time that
MZ, while not a significant component of a normal diet,
is nonetheless absorbed into the serum. The subjects were
not on controlled diets and this could account, at least in
part, for the very different responses that were observed.
The L, Z and MZ in the supplement were in the ratio
1.0:0.3:2.7 while, in the serum, the increases in these car-
otenoids resulting from supplementation were in the ratio
1.0:4.3:4.4 for subject A, and 1.0:0.43:0.47 for subject B.
Thus the serum responses for these two subjects revealed
no common pattern, and the relative efficiencies with
which L, Z and MZ are absorbed into the serum cannot be
proposed without the benefit a larger study involving
more subjects and a detailed knowledge of their individ-
ual diets. Data from the reversed-phase HPLC analysis of
serum L and combined Z + MZ in the other 10 subjects in
the supplementation group were reasonably consistent
with expectations based on the composition of the sup-
plement. In the supplement, the L:Z + MZ ratio was
1.0:3.0. In the serum, averaged for all 10 subjects, the
increases in L and Z + MZ resulting from supplementation
were in the ratio1.0:2.2. There was a slight trend towards
larger increases in L and Z+MZ in subjects whose pre-sup-
plementation levels of these carotenoids were lower, but
not at the level of statistical significance.
The magnitudes of the average increases in L and Z+MZ in
the supplemented subjects were quite modest in compar-
ison with those reported in subjects supplemented with
comparable amounts of L only or Z only. For example, an
average ~3-fold increase in serum L was reported in sub-
jects taking 5 mg of L per day for 6 months [32]. In
another 6 month study, subjects received a daily dose of
either 10 mg of L, 10 mg of Z, or 10 mg of L combined
with 10 mg of Z [33]. The average serum L increase was
~7-fold for the L group, the average serum Z increase was
~27-fold for the Z group, and the average serum L and Z
increases were ~4-fold and 14-fold respectively for the
group receiving both L and Z. A likely factor influencing
the bioavailability of the carotenoid is the formulation of
the supplement. There is also some evidence for competi-
tion among carotenoids for uptake into the serum when
administered in combination [34]. Both of these factors
may have been influential in the present study.
Consistent with other L and Z supplementation studies
[30,31], MP responses were varied in terms of the
increases in MPOD among the 10 subjects in the supple-
mentation group. Four subjects had significant rates of
increase in MPOD in both eyes, and 4 others had signifi-
cant rates of increase in one eye only. The average rate ±
Macular pigment optical density (MPOD) response to supple- mentation in the left eye of subject # 1 (filled circles) and the  right eye of subject # 6 (open circles) Figure 2
Macular pigment optical density (MPOD) response to supple-
mentation in the left eye of subject # 1 (filled circles) and the 
right eye of subject # 6 (open circles). Supplementation 
began on day zero.Nutrition & Metabolism 2007, 4:12 http://www.nutritionandmetabolism.com/content/4/1/12
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SD for the group was 0.59 ± 0.79 mAU/day. For the pla-
cebo group, there were no significant rates of increase, and
the average ± SD was -0.17 ± 0.42 mAU/day. According to
a 2-sided t-test, the averages for the 2 groups differed sig-
nificantly (p < 0.002). The results obtained for the supple-
mentation group may be compared with our earlier
studies in which we reported results averaging 1.13 ± 0.10
mAU/day for a 30 mg/day L study using 2 subjects [31]
and 0.48 ± 0.16 mAU/day for a 30 mg/day Z study, again
using 2 subjects [30]. On a per milligram basis, the aver-
age rate of increase in MPOD obtained in the current
study is very similar to that obtained in the L study and
approximately double the value obtained in the Z study.
However, judgment in making these comparisons should
be tentative based on the small numbers of subjects in the
earlier studies.
For this small study, we found no correlation between the
rate of increase in MPOD in the supplemented subjects
and either the plateau concentration (week 6 to the end of
supplementation), or the change in concentration, of L or
Z+MZ. However, when we restricted our analysis to those
subjects who were more skillful in HFP, as judged by the
scatter in their data, an interesting trend emerged. For sub-
jects whose rates of change in MPOD were accompanied
by a standard error ≤ 0.21 mAU/day, these rates were pos-
itively correlated with the increase in serum Z+MZ (R2 =
0.31), though not quite reaching the level of statistical sig-
nificance (p = 0.078). Therefore it is possible that the MP
responses that we observed in our subjects were due in
large part to the presence of the major constituent of the
supplement, MZ, that was ~10 times as abundant as Z.
However, a final conclusion must await testing of a sup-
plement containing MZ only.
Subject #5 in the supplementation group produced an
anomalous result consisting of significant rates of increase
and decrease in MPOD in the left and right eyes respec-
tively. Assuming that this subject was providing reliable
data, the decrease seen in the right eye may have been due
to a faster build-up of MP at 8° eccentricity compared
with the fovea, as discussed earlier. Significant decreases
in MPOD in the placebo group may have been due to a
change of diet during the study period.
Data from the current and previous studies are limited by
sample size, making it difficult to argue in support of any
one of the three carotenoids, L, Z, or MZ, as the preferred
means of raising MP density. On the other hand, we know
that a significant fraction of L in the central retina is con-
verted to MZ. In the center of the retina, the ratio of MZ to
L is highest and approaching 1:1. This observation sug-
gests that the efficiency of conversion of L to MZ is gener-
ally below 50%. Furthermore, it is possible that the
conversion process may involve a net destruction of caro-
tenoid. As evidence, data from autopsy eyes indicate that
the (L + MZ):Z ratio varies throughout the retina from
~2:1 in the center, where most of the conversion is occur-
ring, to ~3:1 in the periphery [7]. Thus there may be an
advantage in providing MZ in a supplement at the
expense of L if the goal is to raise the overall zeaxanthin
level and potentially improve the degree of retinal protec-
tion.
Table 3: Macular pigment optical density (MPOD) response to placebo. See Table 2 for details.
Subject/eye MPOD pre AU SD pre AU Rate of change in MPOD ± SE, mAU/day p Significance of rate of change
11/L 0.244 0.034 0.01 ± 0.43 0.99 No signif. change
11/R 0.246 0.055 -0.20 ± 0.26 0.46 No signif. change
12/L 0.570 0.043 -0.99 ± 0.23 0.0001 Signif. decrease
12/R 0.551 0.105 -0.10 ± 0.22 0.65 No signif. change
13/L 0.473 0.065 0.00 ± 0.30 0.99 No signif. change
13/R 0.397 0.077 0.66 ± 0.41 0.12 No signif. change
14/L 0.825 0.067 0.03 ± 0.94 0.98 No signif. change
14/R 0.922 0.186 0.36 ± 0.33 0.30 No signif. change
15/L 0.328 0.050 0.14 ± 0.22 0.53 No signif. change
15/R 0.334 0.058 -0.11 ± 0.24 0.66 No signif. change
16/L 0.492 0.048 -0.72 ± 0.16 <0.0001 Signif. decrease
16/R 0.527 0.022 -0.60 ± 0.18 0.0020 Signif. decrease
17/L 0.579 0.036 -0.64 ± 0.87 0.48 No signif. change
17/R 0.482 0.054 -0.32 ± 0.49 0.52 No signif. change
18/L 0.628 0.041 -0.28 ± 0.30 0.36 No signif. change
18/R 0.625 0.057 0.43 ± 0.28 0.13 No signif. change
19/L 0.739 0.143 -0.44 ± 0.33 0.19 No signif. change
19/R 0.693 0.076 -0.30 ± 0.36 0.41 No signif. changeNutrition & Metabolism 2007, 4:12 http://www.nutritionandmetabolism.com/content/4/1/12
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Conclusion
Our study shows that a supplement containing the macu-
lar carotenoids, L, Z and MZ, but principally MZ, is effec-
tive at raising MPOD in the majority of subjects. Increased
MPOD may be an effective means of protecting the aging
population from AMD.
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